RET and thyroid cancer: Pralsetinib approved indications (accelerated approval) were subsequently expanded in December 2020 to the treatment of advanced or metastatic RET-mutant MTC (in patients who require systemic therapy) and advanced or metastatic RET fusion–positive thyroid cancer (in patients who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate)) [7,23].